Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Income Before Tax

Profit after all operating and non-operating items but before income tax.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$50.22M, compared with -$31.63M a year earlier. Trailing-twelve-month income before tax was -$29.91M.

Context

  • Income before tax amounted to 7973.3% of revenue in FY2025, up 6610.6 pp from a year earlier.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$50.22M or moves back toward the trailing-twelve-month quarterly average of -$7.48M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$50.22M-23.0% QoQ
Last fiscal yearDec 2025
-$162.34M-91.1% YoY
LTMJun 2026
-$29.91M+73.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.8%——
1 year-91.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(162.34M) USD
Year-over-year change
-91.1%

Income Before Tax vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's LTM Jun 2026 income before tax of -$29.91M is the 3rd highest of the 10 companies compared; the peer median is -$160.97M.
  • Its year-over-year change of +73.9% is the 3rd highest of 10, against a peer median of -75.2%.
  • Income before tax amounts to 1570.9% of revenue for DNTH, versus a peer median of 6574.5%.
DNTH Competitors Peer median
Income Before Tax for DNTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M +157.0%—61.9%
ANABAnaptysBio, Inc.LTM Mar 2026-$26.63M +81.1%—11.5%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.91M +73.9%—1570.9%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.28M -258.9%—86379.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M -34.3%——
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$160.97M -323.3%—9068.6%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$258.39M -75.2%——
VERAVera Therapeutics, Inc.LTM Jun 2026-$401.89M -84.1%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$440.71M -86.7%—5957.2%
IMVTImmunovant, Inc.LTM Sep 2026-$510.25M -10.3%—7191.7%
Peer median (excluding DNTH) -$160.97M-75.2%—6574.5%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.48M6.42M2.83M6.24M2.04M
Cost of Revenue00000
Gross Profit1.48M6.42M2.83M6.24M2.04M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development12.61M29.38M32.84M83.11M145.64M
Selling, General & Admin1.96M6.74M18.16M24.99M34.33M
Operating Expenses14.56M36.12M51M108.1M179.97M
Depreciation & Amortization2.02M147K355K412K428K
EBITDA(11.09M)(28.33M)(43.2M)(84.56M)(161.91M)
EBITDA Margin-751.3%-441.5%-1528.7%-1356.2%-7952.3%
Operating Income(13.09M)(29.71M)(48.17M)(101.86M)(177.93M)
Operating Margin-886.6%-462.9%-1704.7%-1633.7%-8739.3%
Interest Income100K1.15M4.76M17.37M16.12M
Interest Expense00000
Other Income / Expenses(23K)1.23M4.62M16.9M15.6M
Income Before Tax(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Pre-Tax Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
Income Tax Expense00000
Net Income(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Net Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
EPS (Basic)(3.82)(7.60)(8.45)(2.55)(4.20)
EPS (Diluted)(3.82)(7.60)(8.45)(2.55)(4.20)
Weighted Avg Shares3.43M3.75M5.15M33.31M37.79M
Weighted Avg Shares (Diluted)3.43M3.75M5.15M33.31M37.79M

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.